SCHEMBL16208751

SCHEMBL16208751

CC(=O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.78
ALB P02768 1/20 0.78
MAOA P21397 1/20 0.78
CNR1 P21554 1/20 0.78
DRD1 P21728 1/20 0.78
OPRD1 P41143 1/20 0.78
PDE4D Q08499 1/20 0.78
PDE3A Q14432 1/20 0.78
RAB9A P51151 6/20 0.51
NPC1 O15118 5/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
HDAC6 Q9UBN7 5/20 0.51
CASP3 P42574 2/20 0.49
SENP7 Q9BQF6 2/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
MAPT P10636 3/20 0.48
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23703798 0.87 TTR (0.80) TTRALBMAOACNR1DRD1
SCHEMBL30049107 0.87 TTR (0.80) TTRALBMAOACNR1DRD1
Tafamidis SCHEMBL29361223 0.87 TTR (1.00) TTRALBMAOACNR1DRD1
Tafamidis SCHEMBL442508 0.87 TTR (1.00) TTRALBMAOACNR1DRD1
SCHEMBL26740373 0.86 TTR (0.59) TTRALBMAOACNR1DRD1
Tafamidis SCHEMBL25398819 0.86 TTR (0.97) TTRALBMAOACNR1DRD1
SCHEMBL24928583 0.86 TTR (0.78) TTRALBMAOACNR1DRD1
SCHEMBL24363660 0.85 TTR (0.72) TTRALBMAOACNR1DRD1
SCHEMBL23729105 0.85 TTR (0.72) TTRALBMAOACNR1DRD1
SCHEMBL16689757 0.85 TTR (0.72) TTRALBMAOACNR1DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9499527-B2 Compositions and methods for the treatment of familial amyloid polyneuropathy CELLIX BIO PRIVATE LIMITED (IN) 2016-11-22 US claimed
US-20150126567-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAMILIAL AMYLOID POLYNEUROPATHY CELLIX BIO PRIVATE LIMITED (IN) 2015-05-07 US claimed
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 US disclosed
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 US disclosed
WO-2021154842-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. (US) 2021-08-05 WO disclosed
WO-2014174425-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORTHOSTASIS AND NEUROLOGICAL DISEASES KANDULA MAHESH (IN) 2014-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING TTR, TTPA, TNNC1 TTR 1/4885ALB 8/4885MAOA 3300/4885
US-20150126567-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAMILIAL AMYLOID POLYNEUROPATHY TTR, TNNC1, APP TTR 1/4885ALB 44/4885MAOA 2869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.